vs
Side-by-side financial comparison of NORTHERN TECHNOLOGIES INTERNATIONAL CORP (NTIC) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
NORTHERN TECHNOLOGIES INTERNATIONAL CORP is the larger business by last-quarter revenue ($23.3M vs $18.6M, roughly 1.3× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 1.0%, a 64.7% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 9.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 5.8%).
Maxar Technologies Inc., was an American space technology company, specializing in geospatial intelligence, Earth observation, and on-orbit satellite servicing, satellite products, and related services. DigitalGlobe and MDA Holdings Company merged to become Maxar Technologies on October 5, 2017.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
NTIC vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.3M | $18.6M |
| Net Profit | $237.8K | $12.3M |
| Gross Margin | 36.0% | — |
| Operating Margin | 4.0% | 56.3% |
| Net Margin | 1.0% | 65.7% |
| Revenue YoY | 9.2% | 1808.5% |
| Net Profit YoY | -57.6% | 376.5% |
| EPS (diluted) | $0.03 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.3M | $18.6M | ||
| Q3 25 | $22.3M | $334.0K | ||
| Q2 25 | $21.5M | $1.4M | ||
| Q1 25 | $19.1M | $257.0K | ||
| Q4 24 | $21.3M | $977.0K | ||
| Q3 24 | $23.3M | $660.0K | ||
| Q2 24 | $20.7M | $736.0K | ||
| Q1 24 | $20.8M | $1.4M |
| Q4 25 | $237.8K | $12.3M | ||
| Q3 25 | $-1.1M | $-8.6M | ||
| Q2 25 | $121.8K | $-6.9M | ||
| Q1 25 | $434.3K | $-5.4M | ||
| Q4 24 | $561.1K | — | ||
| Q3 24 | $1.8M | $-2.8M | ||
| Q2 24 | $976.6K | $-14.5M | ||
| Q1 24 | $1.7M | $411.0K |
| Q4 25 | 36.0% | — | ||
| Q3 25 | 37.9% | — | ||
| Q2 25 | 38.4% | — | ||
| Q1 25 | 35.6% | — | ||
| Q4 24 | 38.3% | — | ||
| Q3 24 | 43.8% | — | ||
| Q2 24 | 38.2% | — | ||
| Q1 24 | 40.0% | — |
| Q4 25 | 4.0% | 56.3% | ||
| Q3 25 | 4.2% | -2516.5% | ||
| Q2 25 | 4.0% | -701.0% | ||
| Q1 25 | -1.7% | -3350.2% | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 11.8% | -1563.6% | ||
| Q2 24 | 7.4% | -1255.0% | ||
| Q1 24 | 10.6% | -692.5% |
| Q4 25 | 1.0% | 65.7% | ||
| Q3 25 | -4.9% | -2572.2% | ||
| Q2 25 | 0.6% | -504.8% | ||
| Q1 25 | 2.3% | -2097.7% | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 7.9% | -425.5% | ||
| Q2 24 | 4.7% | -1964.4% | ||
| Q1 24 | 8.2% | 29.9% |
| Q4 25 | $0.03 | $0.25 | ||
| Q3 25 | $-0.11 | $-0.17 | ||
| Q2 25 | $0.01 | $-0.14 | ||
| Q1 25 | $0.04 | $-0.11 | ||
| Q4 24 | $0.06 | — | ||
| Q3 24 | $0.19 | $-0.06 | ||
| Q2 24 | $0.10 | $-0.30 | ||
| Q1 24 | $0.17 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $72.4M | $49.4M |
| Total Assets | $104.0M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $40.0M | ||
| Q3 25 | $7.3M | $37.9M | ||
| Q2 25 | $6.8M | $44.8M | ||
| Q1 25 | $5.1M | $40.6M | ||
| Q4 24 | $5.6M | $59.3M | ||
| Q3 24 | $5.0M | $68.8M | ||
| Q2 24 | $5.8M | $73.0M | ||
| Q1 24 | $4.8M | $80.2M |
| Q4 25 | $72.4M | $49.4M | ||
| Q3 25 | $72.1M | $36.4M | ||
| Q2 25 | $72.4M | $44.5M | ||
| Q1 25 | $69.7M | $50.5M | ||
| Q4 24 | $70.2M | $55.1M | ||
| Q3 24 | $71.2M | $58.5M | ||
| Q2 24 | $68.9M | $60.4M | ||
| Q1 24 | $68.4M | $74.1M |
| Q4 25 | $104.0M | $59.0M | ||
| Q3 25 | $102.7M | $51.1M | ||
| Q2 25 | $99.3M | $60.7M | ||
| Q1 25 | $93.7M | $67.9M | ||
| Q4 24 | $94.0M | $90.6M | ||
| Q3 24 | $94.7M | $99.0M | ||
| Q2 24 | $89.3M | $107.8M | ||
| Q1 24 | $87.3M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $341.9K | $18.4M |
| Free Cash FlowOCF − Capex | $-479.7K | — |
| FCF MarginFCF / Revenue | -2.1% | — |
| Capex IntensityCapex / Revenue | 3.5% | — |
| Cash ConversionOCF / Net Profit | 1.44× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $341.9K | $18.4M | ||
| Q3 25 | $-1.4M | $-8.7M | ||
| Q2 25 | $609.7K | $-7.5M | ||
| Q1 25 | $803.7K | $-7.5M | ||
| Q4 24 | $2.4M | $-24.0M | ||
| Q3 24 | — | $765.0K | ||
| Q2 24 | $1.9M | $-10.9M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | $-479.7K | — | ||
| Q3 25 | $-1.4M | — | ||
| Q2 25 | $-171.2K | — | ||
| Q1 25 | $293.1K | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $869.4K | — | ||
| Q1 24 | — | — |
| Q4 25 | -2.1% | — | ||
| Q3 25 | -6.3% | — | ||
| Q2 25 | -0.8% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.2% | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.5% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 3.6% | — | ||
| Q1 25 | 2.7% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.44× | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.01× | — | ||
| Q1 25 | 1.85× | — | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.99× | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTIC
| Inside The USA To Unaffiliated Customers | $7.5M | 32% |
| Natur Tec | $6.0M | 26% |
| Acobal | $3.6M | 15% |
| Other | $2.7M | 12% |
| BR | $2.1M | 9% |
| Zerust OY | $1.4M | 6% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
